These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37739106)

  • 1. Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice.
    Kong Q; Zhu H; Gong W; Deng X; Liu B; Dong J
    J Ethnopharmacol; 2024 Jan; 319(Pt 1):117183. PubMed ID: 37739106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways.
    Kong Q; Ma M; Zhang L; Liu S; He S; Wu J; Liu B; Dong J
    Phytomedicine; 2023 Feb; 110():154638. PubMed ID: 36621167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified Bushen Yiqi Formula mitigates pulmonary inflammation and airway remodeling by inhibiting neutrophils chemotaxis and IL17 signaling pathway in rats with COPD.
    Kong Q; Wang B; Zhong Y; Chen W; Sun J; Liu B; Dong J
    J Ethnopharmacol; 2024 Mar; 321():117497. PubMed ID: 38048893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis.
    Yin Y; Wang Y; Wang C; Zhang Y; Qi A; Song J; Xu L; Yang W; Jiao L
    J Ethnopharmacol; 2024 May; 326():117984. PubMed ID: 38428661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphonuclear-MDSCs Facilitate Tumor Regrowth After Radiation by Suppressing CD8
    Zhang Md J; Zhang Md L; Yang Md Y; Liu Md Q; Ma Md H; Huang Md A; Zhao Md Y; Xia Md Z; Liu Md T; Wu Md G
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1533-1546. PubMed ID: 33238192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
    Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
    Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling.
    Zheng Y; Wang N; Wang S; Yang B; Situ H; Zhong L; Lin Y; Wang Z
    Cell Commun Signal; 2020 Mar; 18(1):48. PubMed ID: 32213179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF.
    Fu JL; Hao HF; Wang S; Jiao YN; Li PP; Han SY
    J Ethnopharmacol; 2022 Nov; 298():115607. PubMed ID: 35973634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
    Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
    Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network pharmacology prediction and molecular docking analysis reveal the mechanism of modified Bushen Yiqi formulas on chronic obstructive pulmonary disease.
    Choi W; Wu Y; Li Y; Dong J
    J Gene Med; 2024 Jan; 26(1):e3607. PubMed ID: 37795773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
    Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
    Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
    Liang Y; Wang W; Zhu X; Yu M; Zhou C
    Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
    Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
    J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial.
    Kong Q; Cao Y; Gao Z; Sun J; Zhang H; Du Y; Lv Y; Zhou S; Tang Z; Liu B; Dong J
    Trials; 2022 Feb; 23(1):143. PubMed ID: 35164853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
    Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
    Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.